AWS shares new business momentum milestones and announces three new capabilities for Amazon Connect

SEATTLE, Wash., Sept. 27, 2021—Today at Enterprise Connect, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), shared new business momentum milestones and announced three new capabilities for Amazon Connect that improve contact center agent productivity and provide superior service by making customer interactions more effective, personal, and natural. AWS shared for the first time that tens of thousands of AWS customers are supporting more than 10 million contact center interactions a day on Amazon Connect, an easy-to-use, highly scalable, and cost-effective omnichannel cloud contact center solution. The new features announced today are designed to give agents the right information at the right time to answer customer questions faster, provide fast and secure caller authentication, and make communicating with customers easier and more efficient. To get started with Amazon Connect, visit aws.amazon.com/connect/.

Labcorp completes acquisition of Myriad Autoimmune’s Vectra testing business

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 13, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra ® rheumatoid arthritis (RA) assay.

Labcorp selects Medidata’s Sensor Cloud to expand decentralized clinical trial capabilities, enabling first-in-kind industry partnership for digital biomarker discovery

NEW YORK, N.Y., Sept. 13, 2021 - Medidata, a Dassault Systèmes company, and Labcorp Drug Development, a global company providing clinical laboratory and end-to-end drug development services, today announced they have entered into an agreement using the Medidata Sensor Cloud. Medidata will receive and process medical-grade sensor data within drug, vaccine and device trials across Labcorp Drug Development’s clinical trial portfolio, enhancing their decentralized clinical trial (DCT) offerings.